Overall, Amgen’s key medicines like Evenity, Repatha and Blincyto, as well as newer medicines like Tavneos and Tezspire, drove sales, more than offsetting declining revenues from oncology ...

The U.S. Food and Drug Administration on Tuesday approved Amgen Inc's drug Evenity for the treatment of osteoporosis in postmenopausal women who are at high risk of bone fractures.

With promising trial results and an FDA approval seemingly near, Amgen Inc.'s osteoporosis drug Evenity was expected to contribute at least something to the company's top line this year. But Amgen ...

The U.S. Food and Drug Administration last week approved bone-building Evenity for postmenopausal women who are at high risk of fracture, but required the label to have a boxed warning, the FDA ...

Amgen and UCB’s osteoporosis drug Evenity has finally won over the FDA, thanks to a pared-back indication in high-risk women.

OssiFi-Mab, a small firm in Kansas that is developing osteoporosis drugs, has sued Amgen for patent infringement with its osteoporosis drug Evenity.

AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter.

Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.